Switching patients to a new drug of your own may not be a bad thing.
Normally when you put out a product, you want to take sales away from the competition, not from other products that you sell yourself. But that's exactly what Gilead Sciences (NASDAQ:GILD) is doing, and Motley Fool health care analyst David Williamson thinks it's a great move. Watch the video to find out why.
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.